Global Microscopic Polyangiitis (MPA) Market Insights Forecasts to 2030

• The Market is growing at a CAGR of 5.9% from 2022 to 2032.
• The Worldwide Microscopic Polyangiitis Market size is expected to grow by 2032.
• Asia Pacific is expected to grow the fastest during the forecast period.

Get more details on this report -

Request Free Sample PDF

The Global Microscopic Polyangiitis Market Size is expected to grow by 2032, at a CAGR of 5.9% during the forecast period 2022 to 2032.

 

 Market Overview

Inflammation of blood arteries causes microscopic polyangiitis (MPA), which damages various organs such as primarily the kidney, lungs, nerves, skin, and joints. Myalgia-related microscopic polyangiitis can also affect the muscles, but examples in which necrotizing vasculitis was discovered in a muscle biopsy specimen are uncommon. Although microscopic polyangiitis is an immune system-mediated illness, the precise cause of immune system malfunction is unknown. As microscopic polyangiitis affects several organs, it can cause a variety of symptoms, including sickness, fever, weight loss, loss of appetite, bloody coughing in the case of the lungs, and loss of feeling when it comes to the nerves. Red blood cells (RBCs) and antineutrophil cytoplasmic antibodies (ANCA) blood tests, as well as imaging techniques like computed tomography (CT), magnetic resonance (MR) scans, and X-rays, are all employed in the diagnosis. The presence of microscopic polyangiitis can be determined through biopsy (tissue sample testing) if the findings of these tests are positive for the condition.

 

Report Coverage

This research report categorizes the global microscopic polyangiitis market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global microscopic polyangiitis market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global microscopic polyangiitis market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

 

 

Driving Factors

Global microscopic polyangiitis growth is anticipated to be driven by key players introducing novel treatment options during the forecast period. For example, InflaRx N.V., a German clinical-stage biopharmaceutical company, received FDA approval in July 2018 to conduct phase 2 clinical trials to evaluate the safety and efficacy of IFX-1 for treating anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, the presence of which signifies microscopic polyangiitis in the patient. Also, the global microscopic polyangiitis market is anticipated to develop over the projected period, driven by the approval of new treatments. Moreover, the government's increasing efforts to raise public awareness of rare diseases and their effects along with increased funding from the government, are anticipated to drive the growth of the microscopic polyangiitis market globally. The rising R&D efforts and continuing clinical studies for the treatment of microscopic polyangiitis would increase market potential during the projected period.

 

Restraining Factors

Due to the difficulty in diagnosing microscopic polyangiitis and the fact that its symptoms can be misinterpreted for those of many other diseases, this ailment is rare and its etiology is unclear, so the market's growth would be hampered. The adverse effects of corticosteroids include skin thinning and excruciating discomfort is hinder market growth. Also, azathioprine can cause adverse reactions like diarrhea, joint discomfort, loss of coordination, seizures, and altered eyesight over the projected period, these factors will likely restrict the growth of the microscopic polyangiitis market globally. The global market for microscopic polyangiitis would be retrained and challenged during the forecast period due to the high cost of medications and lack of authorized treatments and therapies.

 

Market Segmentation

In 2022, the rituximab segment is dominate the market with the largest market share during the forecast period.

Based on the drug, the global microscopic polyangiitis market is classified into rituximab, azathioprine, cyclophosphamide, prednisone, pipeline drugs, and others. Among these, the rituximab segment is dominate the market during the forecast period.

 

In 2022, the injectable segment is driving the market with the largest market share over the forecast period.

Based on the route of administration, the global microscopic polyangiitis market is divided into oral and injectable. Throughout these segments, the injectable segment is holding the largest market share over the forecast period, owing to some of the commonly used drugs for microscopic polyangiitis, such as Cyclophosphamide, being administered intravenously (IV) or subcutaneously (SC) as injections.

 

In 2022, the hospital pharmacies segment is influencing the market share growth during the forecast period.

Based on the distribution channel, the global microscopic polyangiitis market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment is expected to grow the market during the forecast period This is because this illness is a serious medical illness that frequently requires hospitalization and strict supervision by medical personnel. As a result, hospital pharmacists distribute the majority of the drugs used to treat microscopic polyangiitis.

 

Regional Segment Analysis of the microscopic polyangiitis (MPA) market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is driving the largest market share over the forecast period

 

Get more details on this report -

Request Free Sample PDF

 

North America holds the largest market share of microscopic polyangiitis, due to the presence of significant key companies, the high prevalence rate, and rising social awareness. Furthermore, the well-developed healthcare sector and an increase in government support for research & development in this region may dominate the market growth of microscopic polyangiitis.

 

The Asia-Pacific is expected to grow the market during the forecast period due to increasing product launches, and the advancement of therapies for the treatment of rare diseases. Moreover, the growing government support and rising healthcare expenditure are also expected to propel the growth of the microscopic polyangiitis market during the forecast period.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global microscopic polyangiitis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Genentech, Inc.
• Celltrion, Inc.
• InflaRx N.V.
• ChemoCentryx Inc.
• Bristol-Myers Squibb Company
• Teijin Pharma Ltd
• Amerigen Pharmaceuticals Limited
• Sandoz International GmbH
• TTY Biopharm Company Ltd.

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In January 2022, according to an update from the French Vasculitis Study Group. The clinical trials for Rituximab's effectiveness and safety in the treatment of microscopic polyangiitis with a favorable prognosis are currently in phase 3 and are expected to be finished by 2024.  

 

• In December 2020, RIABNI (rituximab-arrx), a biosimilar of Rituxan (rituximab), was licensed by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis (MPA).

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Microscopic Polyangiitis (MPA) Market based on the below-mentioned segments:

 

Global Microscopic Polyangiitis (MPA) Market, By Drug

• Rituximab
• Azathioprine
• Cyclophosphamide
• Prednisone
• Pipeline Drugs
• Others

 

Global Microscopic Polyangiitis Market, By Route of Administration

• Oral
• Injectable

 

Global Microscopic Polyangiitis Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 

Microscopic Polyangiitis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

  .